PEOPLE - Roche makes appointment:
This article was originally published in Clinica
Shayesteh Furst-Ladani is to leave Baxter to become global regulatory affairs manager for development products and licensing at Roche. Dr Furst-Ladani is a leading expert in human tissue engineered product regulation and was recently elected chairperson of the human tissue/cell working group at the European bioindustry association, EuropaBio. She is now working her notice as manager of regulatory affairs global product development, biosurgery, at Baxter BioScience.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.